{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:52:22Z","timestamp":1785840742769,"version":"3.56.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Maryse and William Brock Chair for Clinical Research into Stem Cell Transplantation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41409-026-02902-4","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:19:52Z","timestamp":1781018392000},"page":"1041-1051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for EBV reactivation and impact of graft composition following GVHD prophylaxis with rabbit ATG or PTCy"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7950-9354","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Thiant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-0164","authenticated-orcid":false,"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Delisle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-3374","authenticated-orcid":false,"given":"Omar Eduardo","family":"Fernandez-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7882-9335","authenticated-orcid":false,"given":"Silvy","family":"Lachance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis Claude","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Veilleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Gisela Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-7266","authenticated-orcid":false,"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7716-6864","authenticated-orcid":false,"given":"Jean","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2902_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/bmt.2016.19","volume":"51","author":"DM Burns","year":"2016","unstructured":"Burns DM, Rana S, Martin E, Nagra S, Ward J, Osman H, et al. Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transpl. 2016;51:825\u201332. https:\/\/doi.org\/10.1038\/bmt.2016.19.","journal-title":"Bone Marrow Transpl"},{"key":"2902_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s12185-016-2062-7","volume":"104","author":"L Fu","year":"2016","unstructured":"Fu L, Wang J, Wei N, Wu L, Wang Y, Huang W, et al. Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single-center analysis. Int J Hematol. 2016;104:628\u201335. https:\/\/doi.org\/10.1007\/s12185-016-2062-7.","journal-title":"Int J Hematol"},{"key":"2902_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/tid.12618","volume":"18","author":"M Raberahona","year":"2016","unstructured":"Raberahona M, Wackenheim C, Germi R, Carr\u00e9 M, Bulabois CE, Thi\u00e9baut A, et al. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy. Transpl Infect Dis. 2016;18:889\u201395. https:\/\/doi.org\/10.1111\/tid.12618.","journal-title":"Transpl Infect Dis"},{"key":"2902_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jcyt.2018.02.367","volume":"20","author":"A Kalra","year":"2018","unstructured":"Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, et al. Epstein-Barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder. Cytotherapy. 2018;20:706\u201314. https:\/\/doi.org\/10.1016\/j.jcyt.2018.02.367.","journal-title":"Cytotherapy"},{"key":"2902_CR5","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.bbmt.2018.07.008","volume":"24","author":"AD Law","year":"2018","unstructured":"Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, Kim DDH, et al. Reduced-Intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies. Biol Blood Marrow Transpl. 2018;24:2259\u201364. https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.008.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2902_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.retram.2019.03.001","volume":"67","author":"B Delapierre","year":"2019","unstructured":"Delapierre B, Reman O, Dina J, Breuil C, Bellal M, Johnson-Ansah H, et al. Low-dose Rituximab for pre-emptive treatment of Epstein-Barr virus reactivation after allogenic hematopoietic stem cell transplantation. Curr Res Transl Med. 2019;67:145\u20138. https:\/\/doi.org\/10.1016\/j.retram.2019.03.001.","journal-title":"Curr Res Transl Med"},{"key":"2902_CR7","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.bbmt.2019.05.020","volume":"25","author":"B Figgins","year":"2019","unstructured":"Figgins B, Hammerstrom A, Ariza-Heredia E, Oran B, Milton DR, Yeh J. Characterization of viral infections after antithymocyte globulin-based conditioning in adults undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:1837\u201343. https:\/\/doi.org\/10.1016\/j.bbmt.2019.05.020.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2902_CR8","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s00277-019-03742-7","volume":"98","author":"XN Gao","year":"2019","unstructured":"Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, et al. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies. Ann Hematol. 2019;98:2163\u201377. https:\/\/doi.org\/10.1007\/s00277-019-03742-7.","journal-title":"Ann Hematol"},{"key":"2902_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1393-7","volume":"17","author":"R Lin","year":"2019","unstructured":"Lin R, Wang Y, Huang F, Fan Z, Zhang S, Yang T, et al. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study. BMC Med. 2019;17:156. https:\/\/doi.org\/10.1186\/s12916-019-1393-7.","journal-title":"BMC Med"},{"key":"2902_CR10","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3892\/mmr.2018.9794","volume":"19","author":"J Marinho-Dias","year":"2019","unstructured":"Marinho-Dias J, Baldaque I, Pinho-Vaz C, Leite L, Branca R, Campilho F, et al. Association of Epstein\u2011Barr virus infection with allogeneic hematopoietic stem cell transplantation in patients in Portugal. Mol Med Rep. 2019;19:1435\u201342. https:\/\/doi.org\/10.3892\/mmr.2018.9794.","journal-title":"Mol Med Rep"},{"key":"2902_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.hemonc.2018.11.002","volume":"12","author":"GR Mohyuddin","year":"2019","unstructured":"Mohyuddin GR, Roller J, Shune L, Lin T, Dias A, Ganguly S, et al. Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. Hematol Oncol Stem Cell Ther. 2019;12:171\u20133. https:\/\/doi.org\/10.1016\/j.hemonc.2018.11.002.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2902_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00277-019-03603-3","volume":"98","author":"H Wang","year":"2019","unstructured":"Wang H, Zhang TT, Qi JQ, Chu TT, Miao M, Qiu HY, et al. Incidence, risk factors, and clinical significance of Epstein\u2013Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation. Ann Hematol. 2019;98:987\u201396. https:\/\/doi.org\/10.1007\/s00277-019-03603-3.","journal-title":"Ann Hematol"},{"key":"2902_CR13","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41409-020-0831-7","volume":"55","author":"Y Ru","year":"2020","unstructured":"Ru Y, Zhang X, Song T, Ding Y, Zhu Z, Fan Y, et al. Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes. Bone Marrow Transpl. 2020;55:1754\u201362. https:\/\/doi.org\/10.1038\/s41409-020-0831-7.","journal-title":"Bone Marrow Transpl"},{"key":"2902_CR14","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1080\/10428194.2020.1797010","volume":"61","author":"MQ Salas","year":"2020","unstructured":"Salas MQ, Prem S, Remberger M, Lam W, Kim DDH, Michelis FV, et al. High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. Leuk Lymphoma. 2020;61:3198\u2013208. https:\/\/doi.org\/10.1080\/10428194.2020.1797010.","journal-title":"Leuk Lymphoma"},{"key":"2902_CR15","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00277-021-04528-6","volume":"100","author":"P Ke","year":"2021","unstructured":"Ke P, Zhang X, Liu S, Zhu Q, Ma X, Chen F, et al. The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen. Ann Hematol. 2021;100:1879\u201389. https:\/\/doi.org\/10.1007\/s00277-021-04528-6.","journal-title":"Ann Hematol"},{"key":"2902_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s00277-021-04563-3","volume":"100","author":"S Macy","year":"2021","unstructured":"Macy S, Passweg J, Medinger M. Incidence and impact of Epstein-Barr virus events in the early phase after allogeneic hematopoietic cell transplantation. Ann Hematol. 2021;100:1913\u20135. https:\/\/doi.org\/10.1007\/s00277-021-04563-3.","journal-title":"Ann Hematol"},{"key":"2902_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13719","volume":"23","author":"J Lindsay","year":"2021","unstructured":"Lindsay J, Othman J, Yong MK, Ritchie D, Chee L, Tay K, et al. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant. Transpl Infect Dis. 2021;23:e13719. https:\/\/doi.org\/10.1111\/tid.13719.","journal-title":"Transpl Infect Dis"},{"key":"2902_CR18","doi-asserted-by":"publisher","first-page":"682.e1","DOI":"10.1016\/j.jtct.2021.04.020","volume":"27","author":"MAV Marzolini","year":"2021","unstructured":"Marzolini MAV, Wilson AJ, Sanchez E, Carpenter B, Chakraverty R, Hough R, et al. Natural history of Epstein-Barr virus replication and viral load dynamics after alemtuzumab-based allogeneic stem cell transplantation. Transpl Cell Ther. 2021;27:682.e1\u2013682.e12. https:\/\/doi.org\/10.1016\/j.jtct.2021.04.020.","journal-title":"Transpl Cell Ther"},{"key":"2902_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12185-021-03280-x","volume":"115","author":"TT Chen","year":"2022","unstructured":"Chen TT, Lin CC, Lo WJ, Hsieh CY, Lien MY, Lin CH, et al. Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies. Int J Hematol. 2022;115:525\u201333. https:\/\/doi.org\/10.1007\/s12185-021-03280-x.","journal-title":"Int J Hematol"},{"key":"2902_CR20","doi-asserted-by":"publisher","first-page":"53.e1","DOI":"10.1016\/j.jtct.2021.09.021","volume":"28","author":"M Kinzel","year":"2022","unstructured":"Kinzel M, Dowhan M, Kalra A, Williamson TS, Dabas R, Jamani K, et al. Risk Factors for the incidence of and the mortality due to post-transplant lymphoproliferative disorder after hematopoietic cell transplantation. Transpl Cell Ther. 2022;28:53.e1\u201353.e10. https:\/\/doi.org\/10.1016\/j.jtct.2021.09.021.","journal-title":"Transpl Cell Ther"},{"key":"2902_CR21","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.3390\/curroncol31050211","volume":"31","author":"C Ratiu","year":"2024","unstructured":"Ratiu C, Dufresne SF, Thiant S, Roy J. Epstein\u2013Barr virus monitoring after an allogeneic hematopoietic stem cell transplant: review of the recent data and current practices in Canada. Curr Oncol. 2024;31:2780\u201395. https:\/\/doi.org\/10.3390\/curroncol31050211.","journal-title":"Curr Oncol"},{"key":"2902_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1182\/asheducation-2013.1.95","volume":"2013","author":"H Zimmermann","year":"2013","unstructured":"Zimmermann H, Trappe RU. EBV and posttransplantation lymphoproliferative disease: what to do? Hematology. 2013;2013:95\u2013102. https:\/\/doi.org\/10.1182\/asheducation-2013.1.95.","journal-title":"Hematology"},{"key":"2902_CR23","doi-asserted-by":"crossref","unstructured":"Ahmad I, Cau NV, Kwan J, Maaroufi Y, Meuleman N, Aoun M, et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation. 2009;87. https:\/\/journals.lww.com\/transplantjournal\/Fulltext\/2009\/04270\/Preemptive_Management_of_Epstein_Barr_Virus.21.aspx","DOI":"10.1097\/TP.0b013e31819f1c49"},{"key":"2902_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.bbmt.2018.02.026","volume":"24","author":"L Liu","year":"2018","unstructured":"Liu L, Zhang X, Feng S. Epstein-Barr virus-related post-transplantation lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2018;24:1341\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.026.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2902_CR25","doi-asserted-by":"publisher","first-page":"43.e1","DOI":"10.1016\/j.jtct.2022.10.013","volume":"29","author":"M Kinzel","year":"2023","unstructured":"Kinzel M, Kalra A, Khanolkar RA, Williamson TS, Li N, Khan F, et al. Rituximab toxicity after preemptive or therapeutic administration for post-transplant lymphoproliferative disorder. Transpl Cell Ther. 2023;29:43.e1\u201343.e8. https:\/\/doi.org\/10.1016\/j.jtct.2022.10.013.","journal-title":"Transpl Cell Ther"},{"key":"2902_CR26","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1080\/10428194.2021.1948037","volume":"62","author":"S Shimony","year":"2021","unstructured":"Shimony S, Bar-Sever E, Berger T, Itchaki G, Gurion R, Yeshurun M, et al. Late-onset neutropenia after rituximab and obinutuzumab treatment \u2013 characteristics of a class-effect toxicity. Leuk Lymphoma. 2021;62:2921\u20137. https:\/\/doi.org\/10.1080\/10428194.2021.1948037.","journal-title":"Leuk Lymphoma"},{"key":"2902_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903063","volume":"13","author":"SP Kania","year":"2022","unstructured":"Kania SP, Silva JMF, Charles OJ, Booth J, Cheung SYA, Yates JWT, et al. Epstein-Barr virus reactivation after paediatric haematopoietic stem cell transplantation: risk factors and sensitivity analysis of mathematical model. Front Immunol. 2022;13:903063. https:\/\/doi.org\/10.3389\/fimmu.2022.903063.","journal-title":"Front Immunol"},{"key":"2902_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14052","volume":"25","author":"PR Enok Bonong","year":"2021","unstructured":"Enok Bonong PR, Buteau C, Duval M, Lacroix J, Laporte L, Tucci M, et al. Risk factors for post-transplant Epstein-Barr virus events in pediatric recipients of hematopoietic stem cell transplants. Pediatr Transpl. 2021;25:e14052. https:\/\/doi.org\/10.1111\/petr.14052.","journal-title":"Pediatr Transpl"},{"key":"2902_CR29","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.3892\/mmr.2018.9433","volume":"18","author":"J Marinho-Dias","year":"2018","unstructured":"Marinho-Dias J, Lobo J, Henrique R, Baldaque I, Pinho-Vaz C, Regadas L, et al. Post\u2011transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: a single-center retrospective study between 2005 and 2012. Mol Med Rep. 2018;18:4650\u20136. https:\/\/doi.org\/10.3892\/mmr.2018.9433.","journal-title":"Mol Med Rep"},{"key":"2902_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13319","volume":"23","author":"S Ali","year":"2019","unstructured":"Ali S, AlThubaiti S, Renzi S, Krueger J, Chiang KY, Naqvi A, et al. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Pediatr Transpl. 2019;23:e13319. https:\/\/doi.org\/10.1111\/petr.13319.","journal-title":"Pediatr Transpl"},{"key":"2902_CR31","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.bbmt.2013.07.013","volume":"19","author":"JA Kanakry","year":"2013","unstructured":"Kanakry JA, Kasamon YL, Bola\u00f1os-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, et al. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013;19:1514\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2013.07.013.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2902_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/tid.12365","volume":"17","author":"R Crocchiolo","year":"2015","unstructured":"Crocchiolo R, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis. 2015;17:242\u20139. https:\/\/doi.org\/10.1111\/tid.12365.","journal-title":"Transpl Infect Dis"},{"key":"2902_CR33","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/s41409-021-01328-4","volume":"56","author":"A Esquirol","year":"2021","unstructured":"Esquirol A, Pascual MJ, Kwon M, P\u00e9rez A, Parody R, Ferra C, et al. Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transpl. 2021;56:2432\u201344. https:\/\/doi.org\/10.1038\/s41409-021-01328-4.","journal-title":"Bone Marrow Transpl"},{"key":"2902_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/20406207251335477","volume":"16","author":"L Ma","year":"2025","unstructured":"Ma L, Zhang Y, Wang T, Cai Y, Yang J, Tong Y, et al. Epstein\u2013Barr virus reactivation after haplo-peripheral blood stem cell transplantation in patients with hematological malignancies: immune reconstitution and influence on survival. Ther Adv Hematol. 2025;16:20406207251335477. https:\/\/doi.org\/10.1177\/20406207251335477.","journal-title":"Ther Adv Hematol"},{"key":"2902_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2022.103360","volume":"71","author":"J Cao","year":"2023","unstructured":"Cao J, Pei R, Lu Y, Zheng Z, Yuan Z, Li D, et al. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome. Curr Res Transl Med. 2023;71:103360. https:\/\/doi.org\/10.1016\/j.retram.2022.103360.","journal-title":"Curr Res Transl Med"},{"key":"2902_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/09636897221079739","volume":"31","author":"X Zhou","year":"2022","unstructured":"Zhou X, Cai Y, Yang J, Tong Y, Qiu H, Huang C, et al. Lower absolute lymphocyte count before conditioning predicts high relapse risk in patients after haploidentical peripheral blood stem cell transplantation with low-dose anti-thymocyte globulin\/post-transplant cyclophosphamide for GvHD Prophylaxis. Cell Transpl. 2022;31:09636897221079739. https:\/\/doi.org\/10.1177\/09636897221079739.","journal-title":"Cell Transpl"},{"key":"2902_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106918","volume":"120","author":"M Barkhordar","year":"2022","unstructured":"Barkhordar M, Kasaeian A, Janbabai G, Mousavi SA, Fumani HK, Tavakoli S, et al. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: a retrospective 10-year experience. Leuk Res. 2022;120:106918. https:\/\/doi.org\/10.1016\/j.leukres.2022.106918.","journal-title":"Leuk Res"},{"key":"2902_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"W Zhang","year":"2023","unstructured":"Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, et al. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine\u2013busulfan\u2013cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: a multicentre, randomized controlled clinical trial. Br J Haematol. 2023;200:210\u201321. https:\/\/doi.org\/10.1111\/bjh.18483.","journal-title":"Br J Haematol"},{"key":"2902_CR39","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/v15030714","volume":"15","author":"H Yu","year":"2023","unstructured":"Yu H, Robertson ES. Epstein\u2013Barr virus history and pathogenesis. Viruses. 2023;15:714. https:\/\/doi.org\/10.3390\/v15030714.","journal-title":"Viruses"},{"key":"2902_CR40","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114\u201325. https:\/\/doi.org\/10.1038\/s41409-020-0803-y.","journal-title":"Bone Marrow Transpl"},{"key":"2902_CR41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641\u201350. https:\/\/doi.org\/10.1016\/j.bbmt.2008.03.005.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2902_CR42","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","volume":"26","author":"A Ruggeri","year":"2020","unstructured":"Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JL, et al. Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2020;26:1915\u201322. https:\/\/doi.org\/10.1016\/j.bbmt.2020.06.026.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2902_CR43","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.bbmt.2018.01.031","volume":"24","author":"P Chiusolo","year":"2018","unstructured":"Chiusolo P, Bug G, Olivieri A, Brune M, Mordini N, Alessandrino PE, et al. A Modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study. Biol Blood Marrow Transpl. 2018;24:1243\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.031.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2902_CR44","unstructured":"Center for International Blood and Marrow Transplant Research (CIBMTR) standards. Available at: www.cibmtr.org."},{"key":"2902_CR45","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1038\/s41375-022-01667-1","volume":"36","author":"H Zimmermann","year":"2022","unstructured":"Zimmermann H, Koenecke C, Dreyling MH, Pott C, D\u00fchrsen U, Hahn D, et al. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial. Leukemia. 2022;36:2468\u201378. https:\/\/doi.org\/10.1038\/s41375-022-01667-1.","journal-title":"Leukemia"},{"key":"2902_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22:1. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2902_CR47","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transpl. 2005;11:945\u201356. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2902_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.567020","volume":"11","author":"F Compagno","year":"2020","unstructured":"Compagno F, Basso S, Panigari A, Bagnarino J, Stoppini L, Maiello A, et al. Management of PTLD after hematopoietic stem cell transplantation: immunological perspectives. Front Immunol. 2020;11:567020. https:\/\/doi.org\/10.3389\/fimmu.2020.567020.","journal-title":"Front Immunol"},{"key":"2902_CR49","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBDO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"key":"2902_CR50","doi-asserted-by":"publisher","first-page":"11451","DOI":"10.18632\/oncotarget.24328","volume":"9","author":"C Reti\u00e8re","year":"2018","unstructured":"Reti\u00e8re C, Willem C, Guillaume T, Vi\u00e9 H, Gautreau-Rolland L, Scotet E, et al. Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Oncotarget. 2018;9:11451\u201364. https:\/\/doi.org\/10.18632\/oncotarget.24328.","journal-title":"Oncotarget"},{"key":"2902_CR51","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3324\/haematol.2020.271445","volume":"107","author":"R Massoud","year":"2021","unstructured":"Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, et al. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. haematol. 2021;107:857\u201367. https:\/\/doi.org\/10.3324\/haematol.2020.271445.","journal-title":"haematol"},{"key":"2902_CR52","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41409-024-02474-1","volume":"60","author":"T Meyer","year":"2025","unstructured":"Meyer T, Maas-Bauer K, W\u00e4sch R, Duyster J, Zeiser R, Finke J, et al. Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis. Bone Marrow Transpl. 2025;60:286\u201396. https:\/\/doi.org\/10.1038\/s41409-024-02474-1.","journal-title":"Bone Marrow Transpl"},{"key":"2902_CR53","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1086\/503838","volume":"42","author":"NE Annels","year":"2006","unstructured":"Annels NE, Kalpoe JS, Bredius RGM, Claas EC, Kroes ACM, Hislop AD, et al. Management of Epstein-Barr Virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis. 2006;42:1743\u20138.","journal-title":"Clin Infect Dis"},{"key":"2902_CR54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10238-023-01270-3","volume":"24","author":"J Huang","year":"2024","unstructured":"Huang J, Pan Z, Wang L, Zhang Z, Huang J, Jiang C, et al. Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation. Clin Exp Med. 2024;24:22. https:\/\/doi.org\/10.1007\/s10238-023-01270-3.","journal-title":"Clin Exp Med"},{"key":"2902_CR55","doi-asserted-by":"publisher","first-page":"e920","DOI":"10.1097\/HS9.0000000000000920","volume":"7","author":"MA Kharfan-Dabaja","year":"2023","unstructured":"Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, et al. Significance of degree of HLA disparity using t-cell replete peripheral blood stem cells from haploidentical donors with posttransplantation cyclophosphamide in AML in first complete hematologic remission: a study of the acute leukemia working party of the EBMT. HemaSphere. 2023;7:e920. https:\/\/doi.org\/10.1097\/HS9.0000000000000920.","journal-title":"HemaSphere"},{"key":"2902_CR56","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.24.00184","volume":"42","author":"BC Shaffer","year":"2024","unstructured":"Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bola\u00f1os-Meade J, Abboud R, et al. Post-transplant cyclophosphamide\u2013based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors. JCO. 2024;42:3277\u201386. https:\/\/doi.org\/10.1200\/JCO.24.00184.","journal-title":"JCO"},{"key":"2902_CR57","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1182\/bloodadvances.2020003110","volume":"4","author":"SR Solomon","year":"2020","unstructured":"Solomon SR, Aubrey MT, Zhang X, Jackson KC, Morris LE, Holland HK, et al. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2020;4:5311\u201321. https:\/\/doi.org\/10.1182\/bloodadvances.2020003110.","journal-title":"Blood Adv"},{"key":"2902_CR58","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/bloodadvances.2019000797","volume":"4","author":"J Zou","year":"2020","unstructured":"Zou J, Ciurea SO, Kongtim P, Yi M, Carmazzi Y, Rondon G, et al. Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Adv. 2020;4:3474\u201385. https:\/\/doi.org\/10.1182\/bloodadvances.2019000797.","journal-title":"Blood Adv"},{"key":"2902_CR59","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","volume":"10","author":"NS Nunes","year":"2019","unstructured":"Nunes NS, Kanakry CG. Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol. 2019;10:2668 https:\/\/doi.org\/10.3389\/fimmu.2019.02668.","journal-title":"Front Immunol"},{"key":"2902_CR60","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/JCI124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Investig. 2019;129:2357\u201373. https:\/\/doi.org\/10.1172\/JCI124218.","journal-title":"J Clin Investig"},{"key":"2902_CR61","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3324\/haematol.2022.281134","volume":"108","author":"M Launspach","year":"2022","unstructured":"Launspach M, Temel D, Ohlendorf E, Zirngibl F, Materne B, Oevermann L, et al. Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study. Haematol. 2022;108:267\u201372. https:\/\/doi.org\/10.3324\/haematol.2022.281134.","journal-title":"Haematol"},{"key":"2902_CR62","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","volume":"5","author":"A Vijenthira","year":"2021","unstructured":"Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5:2624\u201343. https:\/\/doi.org\/10.1182\/bloodadvances.2021004629.","journal-title":"Blood Adv"},{"key":"2902_CR63","first-page":"634","volume":"112","author":"S Mankarious","year":"1988","unstructured":"Mankarious S, Lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA, et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med nov. 1988;112:634\u201340.","journal-title":"J Lab Clin Med nov"},{"key":"2902_CR64","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","volume":"118","author":"OE Yri","year":"2011","unstructured":"Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nord\u00f8y T, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118:6769\u201371. https:\/\/doi.org\/10.1182\/blood-2011-08-372649.","journal-title":"Blood"},{"key":"2902_CR65","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.bbmt.2010.10.002","volume":"17","author":"NC Issa","year":"2011","unstructured":"Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transpl. 2011;17:434\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2010.10.002.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2902_CR66","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","volume":"122","author":"I Nazi","year":"2013","unstructured":"Nazi I, Kelton JG, Larch\u00e9 M, Snider DP, Heddle NM, Crowther MA, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122:1946\u201353. https:\/\/doi.org\/10.1182\/blood-2013-04-494096.","journal-title":"Blood"},{"key":"2902_CR67","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1182\/blood-2006-04-006981","volume":"108","author":"D Jaffe","year":"2006","unstructured":"Jaffe D, Papadopoulos EB, Young JW, O\u2019Reilly RJ, Prockop S, Kernan NA, et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood. 2006;108:2470\u20135. https:\/\/doi.org\/10.1182\/blood-2006-04-006981.","journal-title":"Blood"},{"key":"2902_CR68","doi-asserted-by":"publisher","unstructured":"T\u00fcre Z. Overlooked prophylaxis of Hepatitis B in patients undergoing hematopoietic stem cell transplantation. Erciyes Med J. 2020. https:\/\/doi.org\/10.14744\/etd.2020.36786","DOI":"10.14744\/etd.2020.36786"},{"key":"2902_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102447","volume":"48","author":"D Xiong","year":"2024","unstructured":"Xiong D, Cai W, Zhao W. Risk factors of HBV reactivation in leukemia patients with resolved HBV infection after allogeneic hematopoietic stem cell transplantation. Clin Res Hepatol Gastroenterol. 2024;48:102447. https:\/\/doi.org\/10.1016\/j.clinre.2024.102447.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2902_CR70","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1007\/s00277-020-04206-z","volume":"99","author":"A Murt","year":"2020","unstructured":"Murt A, Elverdi T, Eskazan AE, Salihoglu A, Ar MC, Ongoren S, et al. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle-endemic country. Ann Hematol. 2020;99:2671\u20137. https:\/\/doi.org\/10.1007\/s00277-020-04206-z.","journal-title":"Ann Hematol"},{"key":"2902_CR71","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41409-020-0833-5","volume":"55","author":"K Nishikawa","year":"2020","unstructured":"Nishikawa K, Kimura K, Kanda Y, Sugiyama M, Kakihana K, Doki N, et al. A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2020;55:1388\u201398. https:\/\/doi.org\/10.1038\/s41409-020-0833-5.","journal-title":"Bone Marrow Transpl"},{"key":"2902_CR72","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/vaccines12121449","volume":"12","author":"A Silva-Pinto","year":"2024","unstructured":"Silva-Pinto A, Abreu I, Martins A, Bastos J, Ara\u00fajo J, Pinto R. Vaccination after haematopoietic stem cell transplant: a review of the literature and proposed vaccination protocol. Vaccines. 2024;12:1449 https:\/\/doi.org\/10.3390\/vaccines12121449.","journal-title":"Vaccines"},{"key":"2902_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.967026","volume":"13","author":"X Wei","year":"2022","unstructured":"Wei X, Xie Y, Jiang R, Li H, Wu H, Zhang Y, et al. The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: a real-world study. Front Immunol. 2022;13:967026. https:\/\/doi.org\/10.3389\/fimmu.2022.967026.","journal-title":"Front Immunol"},{"key":"2902_CR74","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1080\/10428194.2018.1543877","volume":"60","author":"K Van Besien","year":"2019","unstructured":"Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, et al. Prophylactic rituximab prevents EBV PTLD in haplocord transplant recipients at high risk. Leuk Lymphoma. 2019;60:1693\u20136. https:\/\/doi.org\/10.1080\/10428194.2018.1543877.","journal-title":"Leuk Lymphoma"},{"key":"2902_CR75","doi-asserted-by":"publisher","first-page":"132.e1","DOI":"10.1016\/j.jtct.2022.10.023","volume":"29","author":"C Patel","year":"2023","unstructured":"Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, et al. Pre-Hematopoietic stem cell transplantation rituximab for Epstein-Barr virus and post-lymphoproliferative disorder prophylaxis in alemtuzumab recipients. Transpl Cell Ther. 2023;29:132.e1\u2013132.e5. https:\/\/doi.org\/10.1016\/j.jtct.2022.10.023.","journal-title":"Transpl Cell Ther"},{"key":"2902_CR76","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/bloodadvances.2021005492","volume":"6","author":"AB Leahy","year":"2022","unstructured":"Leahy AB, Li Y, Talano JA, Elgarten CW, Seif AE, Wang Y, et al. Unrelated donor \u03b1\/\u03b2 T cell\u2013 and B cell\u2013depleted HSCT for the treatment of pediatric acute leukemia. Blood Adv. 2022;6:1175\u201385. https:\/\/doi.org\/10.1182\/bloodadvances.2021005492.","journal-title":"Blood Adv"},{"key":"2902_CR77","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/bmt.2011.28","volume":"47","author":"A Dominietto","year":"2012","unstructured":"Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT, et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transpl. 2012;47:101\u20136. https:\/\/doi.org\/10.1038\/bmt.2011.28.","journal-title":"Bone Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02902-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02902-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02902-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:36:28Z","timestamp":1785839788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02902-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2902"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02902-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IA: consultancy for AbbVie, Jazz Pharmaceuticals, Medexus, Sanofi and Vertex Pharmaceuticals. JR: consultancy for Amgen, Sanofi, Janssen, royalties from sales of UM171. SC: consultancy for the clinical program of ExCellThera, royalties from sales of UM171. JSD: royalties from sales of UM171. SL: royalties from sales of UM171. GS: royalties from sales of UM171. Other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}